MLTX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and its executives violated the Securities Exchange Act of 1934, with claims centered around misleading statements regarding the efficacy of their drug candidate sonelokimab (SLK) compared to a competitor's product [1][3][4]. Group 1: Lawsuit Details - The lawsuit is titled Peters v. MoonLake Immunotherapeutics and is filed in the Southern District of New York [1]. - The class action seeks to represent purchasers or acquirers of MoonLake common stock during the class period [1][2]. - The lead plaintiff motions must be filed by December 15, 2025 [2]. Group 2: Company and Product Information - MoonLake is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [3]. - SLK is the company's sole drug candidate, primarily developed for treating hidradenitis suppurativa (HS) [3]. Group 3: Allegations Against MoonLake - The lawsuit claims that MoonLake made false statements regarding SLK's clinical benefits, asserting that SLK and BIMZELX share the same molecular targets and that SLK's unique structure would not provide superior efficacy [4]. - On September 28, 2025, MoonLake announced Phase 3 VELA program results indicating SLK did not demonstrate competitive efficacy against BIMZELX, leading to a nearly 90% drop in stock price [5].